ENTITY

Lonza Group (LONN SW)

35
Analysis
Health Care • Switzerland
Lonza is a global partner to the pharmaceutical, biotech and nutrition markets. The company works with healthcare customers to develop, manufacture and commercialize medical treatments and technologies to treat patients against a range of diseases. Founded in the Swiss Alps, Lonza now operates across Europe, North America, South America, Asia and Oceania.
more
bearish•Samsung Biologics
•15 Nov 2016 03:49

Samsung Biologics IPO: Another Way for the Company's Relative Valuation

We used price/sales ratio for relative valuation of Samsung Biologics Co., Ltd (207940 KS) , a growing company that has yet to show an operating...

bullish•Samsung Biologics
•11 Nov 2016 06:05

Recap of Samsung BioLogics' First Trading Day - Foreign Institutions Net Purchased 1M Shares

Samsung BioLogics closed at ₩144,000 with 6.67% gain on its first trading day. It started with a relatively weak sentiment at the opening price of...

Logo
320 Views
Share
bullish•Samsung Biologics
•10 Nov 2016 06:20

Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction

As reported by Barron's on Nov 5 ("Samsung BioLogics IPO: Too Expensive"), there are still some skeptical views on BioLogics' IPO valuation....

Logo
404 Views
Share
bullish•Samsung Biologics
•01 Nov 2016 18:11

Samsung BioLogics IPO - Why Investors Are Excited & Concerned

Samsung BioLogics will have a big day tomorrow. Nov 2-3 will be the subscription day. The company has already had a huge success with the...

Logo
429 Views
Share
bearish•Samsung Biologics
•21 Oct 2016 06:54

3 Main Debatable Points to Be Discussed in Samsung BioLogics NDR This Week

Samsung BioLogics is quite busy with NDR this week. BioLogics executives are doing their best to justify the proposed valuation for BioLogics IPO....

Logo
348 Views
Share
x